Pharma Equity Group AS (OCSE:PEG) Profitability Rank: 0 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Pharma Equity Group AS Profitability Rank?

Pharma Equity Group AS has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Pharma Equity Group AS's Operating Margin % for the quarter that ended in Jun. 2026 was %. As of today, Pharma Equity Group AS's Piotroski F-Score is 3.


Pharma Equity Group AS Profitability Rank Related Terms


OCSE:PEG vs VRTX, REGN, MRNA: Profitability Rank Comparison

For the Biotechnology subindustry, Pharma Equity Group AS's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group AS Profitability Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group AS's Profitability Rank falls into.



Pharma Equity Group AS Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Pharma Equity Group AS has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Pharma Equity Group AS's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=-1.281 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Pharma Equity Group AS has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Pharma Equity Group AS Business Description

Address Slotsmarken 12, 1.th, Horsholm, DNK, DK-2970
Pharma Equity Group A/S is a Danish life-science investment company focused on early-stage biotechnology. Through its subsidiary and portfolio holdings, notably Reponex Pharmaceuticals, it develops novel therapies for diseases with unmet medical needs. Its drug candidates, including RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051, target areas such as wound healing, gastrointestinal disorders, and immune-mediated conditions. The group typically acquires or invests in early-stage life-science companies and provides capital, management, and development expertise to advance their pipelines toward clinical trials and commercialization. Its revenue model centers on value appreciation of portfolio companies through milestone payments, licensing agreements, and eventual exits rather than on product sales. Operations are based in Denmark, with activities directed at international pharmaceutical and biotechnology markets. The company is listed on the Nasdaq Copenhagen exchange.